Drug Profile
Research programme: zinc chelators - Interprotein
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator RIKEN
- Developer Interprotein Corporation
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Atopic dermatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Allergic-rhinitis in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Atopic-dermatitis in Japan
- 27 Jan 2006 Early research in Allergic rhinitis in Japan (unspecified route)